ClinicalTrials.gg
CompletedNCT05092438Updated Apr 16, 2025

QIAstat-Dx® Meningitis/Encephalitis Panel Performance Evaluation Study 001

An observational study in Meningitis/Encephalitis, sponsored by QIAGEN Gaithersburg, Inc. Completed at 1 site in United Kingdom. Per ClinicalTrials.gov, last updated 2025-04-16.

Sponsored by QIAGEN Gaithersburg, Inc (part of QIAGEN) · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
595
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Meningitis with a site in United Kingdom — none open to participants now, 1 under way, none of them phase 3. Meningitis · United Kingdom.

Started
2021
with 1 other
Observational
8 of 24
none open now
Registered
19th of 24
by date
Lead sponsor
3 of 24
QIAGEN Gaithersburg, Inc

Among the 24 studies in Meningitis with a site in United Kingdom, this one is one of 2 that started in 2021, is one of 8 observational ones, and was the 19th registered.

Meningitis

268 studies on the registry are indexed under Meningitis; 28 are open to participants now.

Browse Meningitis studies →

Open to participants now

None of the 24 studies in Meningitis with a site in United Kingdom is open now. The open studies under Meningitis, anywhere →

Who these studies take

Of the 17 Meningitis studies recruiting now, 11 (65%) set no upper age limit and 6 (35%) stop at 75 or younger; 7 take children under 18; 2 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 24 studies in Meningitis with a site in United Kingdom as a file.
02

Study summary

Study for performance evaluation of the QIAstat-Dx® Meningitis/Encephalitis Panel in comparison with other chosen comparator methods.

Read the detailed description

This multicenter study aims to evaluate the performance of QIAstat-Dx Meningitis/Encephalitis (ME) Panel with another validated comparator method.

03

Conditions studied

  • Meningitis/Encephalitis
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects (adults and children) with signs and symptoms of meningitis and/or encephalitis

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Residual specimens of CSF obtained by lumbar puncture from subjects with signs and symptoms of meningitis and/or encephalitis following completion of routine testing
  • Specimen that had not been centrifuged Adequate residual volume (≥400 μl)

Exclusion criteria

Exclusion Criteria:

  • Specimens not fitting criteria outlined above
  • CSF obtained from an external ventricular drain or shunt source
  • Lack of clear subject identification or label on residual banked CSF specimen
  • Obvious physical damage of banked residual specimen
  • Repeat specimens from the same subject
05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
595 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. sensitivity

    positive percentage agreement

    Time frame: 6 weeks

  2. specificity

    negative percentage agreement

    Time frame: 6 weeks

07

Study locations

1 site
  • Qiagen
    Manchester, United Kingdom
08

References and documents

Individual participant data

Plan to share: No — all samples are residual and anonymized

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2021 to primary completion in Dec 2021, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2021
First posted
Oct 25, 2021
StartActual
Oct 8, 2021
Primary completionActual
Dec 2, 2021
CompletionActual
Dec 2, 2021
Last update
Apr 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05092438
Responsible party
Sponsor
First posted
Oct 25, 2021
Start date
Oct 8, 2021
Primary completion
Dec 2, 2021
Completion
Dec 2, 2021
Last update
Apr 16, 2025

Study contacts

Sarah Johnson
study director · QIAGEN Gaithersburg, Inc

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion